Supercede Therapeutics, Inc., a startup biotech company focused on small molecule drug development, today announced preclinical efficacy data from its lead therapeutic program to treat obesity.

Merck’s phase 3 HYPERION study of Winrevair meets primary endpoint in recently diagnosed adults with pulmonary arterial hypertension: Rahway, New Jersey Tuesday, June 24, 2025, ...

Topline results were announced from a phase 3 study evaluating sotatercept-csrk in recently diagnosed adults with pulmonary arterial hypertension (PAH).

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID. Please note: If you switch to a different device, you may be ...

Panelists discuss how riociguat targets the nitric oxide pathway and is approved for both Group 1 PAH and Group 4 chronic ...